Director George Kemble filed a Form 4 with the SEC on August 17, 2026, reporting the exercise of stock options and the sale of Series A Common Stock in Sagimet Biosciences Inc. (NASDAQ:SGMT) on August 14, 2026.

Key Highlights

  • Option exercises: George Kemble exercised stock options covering 326,618 shares and 24,369 shares of Series A Common Stock, both at an exercise price of $6.36 per share.
  • Shares sold: Kemble disposed of 350,987 shares of Series A Common Stock at a weighted average price of $10.2328, with individual sale prices ranging from $9.95 to $10.57.
  • Post-transaction ownership: Following all reported transactions, Kemble directly holds 62,161 shares of Series A Common Stock.
  • Remaining options: After the exercises, Kemble holds 31,455 and 11,608 stock options (right to buy), both with an expiration date of 04/27/2029 and an exercise price of $6.36.
  • Rule 10b5-1 plan: All transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2025.
  • Options fully vested: According to the filing, the exercised options were fully vested and exercisable as of the transaction date.

George Kemble's Option Exercises and Share Sales at Sagimet Biosciences

According to the Form 4 filed on August 17, 2026, George Kemble, a director of Sagimet Biosciences Inc. (NASDAQ:SGMT), executed a series of transactions on August 14, 2026. Kemble exercised two tranches of stock options, acquiring 326,618 shares and 24,369 shares of Series A Common Stock at an exercise price of $6.36 per share. The filing notes these options were fully vested and exercisable as of the date of the transactions, and each carried an expiration date of April 27, 2029.

Immediately following the option exercises, Kemble disposed of 350,987 shares of Series A Common Stock. The filing reports a weighted average sale price of $10.2328 per share, reflecting multiple transactions at prices ranging from $9.95 to $10.57, inclusive. The filing states that Kemble undertakes to provide full information regarding the number of shares sold at each separate price within the range upon request from the issuer, any security holder, or SEC staff.

All transactions were carried out pursuant to a Rule 10b5-1 trading plan that Kemble adopted on August 21, 2025, as disclosed in the filing's explanation of responses. After all reported activity, Kemble's direct beneficial ownership in Series A Common Stock stands at 62,161 shares, with remaining stock options totaling 31,455 and 11,608 shares, respectively, both at a $6.36 exercise price. The Form 4 was signed by Elizabeth Rozek as attorney-in-fact on August 17, 2026.

What Was Disclosed

Director George Kemble reported the exercise of stock options for 350,987 total shares of Series A Common Stock at $6.36 and the subsequent sale of those shares at a weighted average of $10.2328, all under a pre-established Rule 10b5-1 plan, leaving him with 62,161 shares directly held.